KR100890462B1 - Pediococcus spissis JNU44 - Google Patents
Pediococcus spissis JNU44 Download PDFInfo
- Publication number
- KR100890462B1 KR100890462B1 KR1020070060639A KR20070060639A KR100890462B1 KR 100890462 B1 KR100890462 B1 KR 100890462B1 KR 1020070060639 A KR1020070060639 A KR 1020070060639A KR 20070060639 A KR20070060639 A KR 20070060639A KR 100890462 B1 KR100890462 B1 KR 100890462B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactobacillus
- pediococcus
- jnu534
- spissis
- kccm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000192001 Pediococcus Species 0.000 title claims abstract description 33
- 108010062877 Bacteriocins Proteins 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 244000005700 microbiome Species 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 14
- 239000003755 preservative agent Substances 0.000 claims abstract description 13
- 230000012010 growth Effects 0.000 claims abstract description 12
- 235000021109 kimchi Nutrition 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 230000002335 preservative effect Effects 0.000 claims abstract description 6
- 241000186660 Lactobacillus Species 0.000 claims description 25
- 229940039696 lactobacillus Drugs 0.000 claims description 25
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 21
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 20
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 20
- 241000186779 Listeria monocytogenes Species 0.000 claims description 8
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 claims description 5
- 240000001929 Lactobacillus brevis Species 0.000 claims description 5
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 5
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000006866 deterioration Effects 0.000 claims description 3
- 230000002906 microbiologic effect Effects 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 claims 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 235000015140 cultured milk Nutrition 0.000 abstract description 2
- 235000013599 spices Nutrition 0.000 abstract description 2
- 210000003608 fece Anatomy 0.000 abstract 2
- 239000010779 crude oil Substances 0.000 abstract 1
- 244000144972 livestock Species 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 16
- 239000004310 lactic acid Substances 0.000 description 11
- 235000014655 lactic acid Nutrition 0.000 description 11
- 240000001046 Lactobacillus acidophilus Species 0.000 description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006872 mrs medium Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 244000199866 Lactobacillus casei Species 0.000 description 4
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- 241000186606 Lactobacillus gasseri Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- 241000218492 Lactobacillus crispatus Species 0.000 description 2
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 229940092559 enterobacter aerogenes Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- IZSRJDGCGRAUAR-MROZADKFSA-M 5-dehydro-D-gluconate Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IZSRJDGCGRAUAR-MROZADKFSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241000186780 Listeria ivanovii Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 241000500340 Pediococcus damnosus Species 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013272 agar well diffusion method Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WISUUJSJSA-N aldehydo-L-xylose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WISUUJSJSA-N 0.000 description 1
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- ZBDGHWFPLXXWRD-JGWLITMVSA-N methyl beta-D-xylopyranoside Chemical compound CO[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O ZBDGHWFPLXXWRD-JGWLITMVSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- TXBNDGDMWKVRQW-UHFFFAOYSA-M sodium;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]acetate;dodecyl sulfate Chemical compound [Na+].OCC(CO)(CO)NCC(O)=O.CCCCCCCCCCCCOS([O-])(=O)=O TXBNDGDMWKVRQW-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23B2/00—Preservation of foods or foodstuffs, in general
- A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
- A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
- A23B2/729—Organic compounds; Microorganisms; Enzymes
- A23B2/7295—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
- A23B2/00—Preservation of foods or foodstuffs, in general
- A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
- A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
- A23B2/729—Organic compounds; Microorganisms; Enzymes
- A23B2/783—Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 원유, 발효유, 김치, 사람의 분변 및 가축의 분변으로부터 분리하며, 유해성 미생물 또는 식품을 변패를 일으키는 미생물의 생육을 억제하는 기능을 갖는 페디오코쿠스 스피시스 JNU534(기탁기관 : 한국종균협회부설 한국미생물보존센터, 수탁번호 : KCCM-10869P호, 수탁일자 : 2007년 5월 2일)에 관한 것으로 상기 페디오코쿠스 스피시스 JNU534 또는 그 배양물을 이용하여 천연방부제, 식품 조성물, 사료용 조성물 및 항균 조성물 등에 광범위하게 사용될 수 있는 페디오코쿠스 스피시스 JNU534에 관한 것이다.The present invention is isolated from crude oil, fermented milk, kimchi, human feces and livestock feces, and has a function of inhibiting the growth of harmful microorganisms or food-causing microorganisms causing decay pediococcus spissis JNU534 (deposit institution: Korea spawn association The Korea Microorganisms Preservation Center, Accession No .: KCCM-10869P, Accession Date: May 2, 2007), using the Pediococcus spissis JNU534 or its cultures, the natural preservative, food composition, feed composition and It relates to Pediococcus spissis JNU534 that can be widely used in antimicrobial compositions and the like.
페디오코쿠스 스피시스, 항균작용, 박테리오신 Pediococcus spice, antibacterial activity, bacteriocin
Description
도 1은 본 발명의 페디오코쿠스 스피시스 JNU534의 옥틸-세파로스 칼럼크로마토그래피로 분별한 결과를 나타내는 그래프이다.1 is a graph showing the results of fractionation by octyl-sepharose column chromatography of pediococcus spissis JNU534 of the present invention.
도 2는 본 발명의 페디오코쿠스 스피시스 JNU534가 생산하는 박테리오신의 열처리시 활성 변화를 나타내는 그래프이다.Figure 2 is a graph showing the change in activity during the heat treatment of the bacteriocin produced by Pediococcus spissis JNU534 of the present invention.
도 3은 본 발명의 페디오코쿠스 스피시스 JNU534가 생산하는 박테리오신의 효소처리에 의한 박테리오신의 활성 변화를 나타내는 그래프이다.Figure 3 is a graph showing the change in activity of bacteriocin by the enzyme treatment of bacteriocin produced by Pediococcus spissis JNU534 of the present invention.
본 발명은 페디오코쿠스 스피시스(Pediococcus Damnosus) JNU534에 관한 것으로, 보다 자세하게는 김치로부터 분리하며, 병원성 또는 부패성 등의 유해성 미생물의 생육을 억제하는 기능이 있어 천연방부제, 식품 조성물, 사료용 조성물 및 항균 조성물 등에 광범위하게 사용될 수 있는 페디오코쿠스 스피시스 JNU534에 관한 것이다.The present invention relates to Pediococcus spissis (Pediococcus Damnosus) JNU534, more specifically, it is separated from kimchi, and has the function of inhibiting the growth of harmful microorganisms, such as pathogenic or decaying, natural preservatives, food compositions, feed compositions and antibacterial It relates to a Pediococcus spissis JNU534 that can be widely used in compositions and the like.
유산균들은 다양한 발효식품의 생산과 저장성 향상 및 사람을 포함한 각종 동물의 장내에 서식하여 미생물총을 조절하고 건강을 증진시키는 등의 중요한 역할을 담당한다.Lactic acid bacteria play an important role in improving the production and storage of various fermented foods and inhabiting the intestines of various animals including humans to control microorganisms and improve health.
특히 상기 유산균이 생산하는 항미생물성 물질 중 박테리오신은 천연 단백질성 물질로 유전적 조작을 통해 생산이 조절될 수 있고 다양한 식품 내 존재하는 병원성 및 부패성 균들의 성장을 억제할 수 있어 박테리오신을 이용한 천연 식품 보존제 개발에 관련된 연구들이 점차 증가되고 있는 추세이다. Especially, among the antimicrobial substances produced by the lactic acid bacteria, bacteriocin is a natural proteinaceous substance, which can be controlled through genetic manipulation and inhibits the growth of pathogenic and decaying bacteria present in various foods. There is an increasing number of studies related to the development of preservatives.
최근 들어 소비자들은 식품의 안전성에 관심이 매우 크며, 인공적인 방부제나 식품첨가물이 적게 들어가거나 전혀 첨가되지 않은 자연식품을 선호하고 있다. Recently, consumers are very concerned about food safety and prefer natural foods with little or no artificial preservatives or food additives.
따라서 화학물질인 방부제나 식품첨가물의 사용을 줄일 수 있는 방법이 시급히 요구되고 있다.Therefore, there is an urgent need for a method of reducing the use of chemical preservatives or food additives.
상기 박테리오신은 미생물이 생산하는 천연의 무독성 방부제로 주목받고 있는 항균성 단백질이며 인체에 섭취되며 소화기관의 단백질 가수 분해 효소에 의해 분해됨으로써, 인체에 무독하고 잔류성이 없다는 점에서 식품 등의 천연 방부제로서의 효용성이 증대되고 있다. The bacteriocin is an antimicrobial protein that is attracting attention as a natural nontoxic preservative produced by microorganisms, and is ingested by the human body and degraded by proteolytic enzymes of the digestive organs, so that it is toxic to humans and has no residual effect. Is increasing.
상기 박테리오신은 또한 비교적 고온에서 불활성화되지 않으며, 광범위한 pH에서 안정성을 갖는 것이 특징이고 무독, 무색, 무취이므로 화학 합성 방부제를 대체할 수 있는 광범위한 용도 개발이 기대된다.The bacteriocins are also inert at relatively high temperatures, are characterized by stability at a wide range of pH, and are toxic, colorless, and odorless, and thus are expected to develop a wide range of applications that can replace chemical synthetic preservatives.
즉, 발효유, 발효 알콜 음료, 통조림, 냉장·냉동제품에서의 저장성 향상 외 에도 고추장, 된장, 두부, 유산균 발효제품 등의 저장성 연장 및 김치, 약주, 탁주 등 전통식품의 산패 및 변질 방지, 어패류의 신선도 유지와 콩나물 등 과실 및 야채류의 저장성을 향상시킬 수 있다.In other words, in addition to improving shelf life in fermented milk, fermented alcoholic beverages, canned food, and refrigerated and frozen products, it extends the shelf life of fermented products such as red pepper paste, soybean paste, tofu, and lactic acid bacteria, and prevents rancidity and deterioration of traditional foods such as kimchi, medicinal wine, and takju. It can improve freshness and shelf life of fruits and vegetables such as bean sprouts.
본 발명의 발명자들은 김치로부터 분리하여 새로운 유산균을 얻는데 성공하였다.The inventors of the present invention succeeded in obtaining new lactic acid bacteria by separating from kimchi.
따라서, 본 발명은 상기와 같은 종래 기술의 제반 단점과 문제점을 해결하기 위한 것으로, 김치로부터 분리하며, 유해성 미생물 또는 식품을 변패를 일으키는 미생물의 생육을 억제하는 기능을 갖는 페디오코쿠스 스피시스 JNU534 또는 그 배양물을 이용하여 천연방부제, 식품 조성물, 사료용 조성물 및 항균 조성물 등에 광범위하게 사용될 수 있는 페디오코쿠스 스피시스 JNU534를 제공함에 본 발명의 목적이 있다.Accordingly, the present invention is to solve the above-mentioned disadvantages and problems of the prior art, it is separated from kimchi, pediococcus spissis JNU534 or has the function of inhibiting the growth of harmful microorganisms or microorganisms causing decay It is an object of the present invention to provide a Pediococcus spissis JNU534 that can be widely used in natural preservatives, food compositions, feed compositions and antimicrobial compositions using the culture.
본 발명의 상기 목적은 유해성 미생물 또는 식품을 변패를 일으키는 미생물의 생육을 억제하는 기능을 갖는 페디오코쿠스 스피시스 JNU534(기탁기관 : 한국종균협회부설 한국미생물보존센터, 수탁번호 : KCCM-10869P호, 수탁일자 : 2007년 5월 2일)에 의해 달성된다.The above object of the present invention has a function of inhibiting the growth of harmful microorganisms or microorganisms that cause deterioration of foods Pediococcus spissis JNU534 (deposit institution: Korea Microbiological Conservation Center affiliated with Korea spawn association, Accession No .: KCCM-10869P, Date of Deposit: May 2, 2007).
또한, 본 발명의 상기 목적은 상기 페디오코쿠스 스피시스 JNU534가 김치로 부터 분리 가능한 것을 특징으로 하는 페디오코쿠스 스피시스 JNU534에 의해서도 달성된다.In addition, the above object of the present invention is also achieved by the Pediococcus spissis JNU534, characterized in that the Pediococcus spissis JNU534 is separable from kimchi.
또한, 본 발명의 상기 목적은 상기 유해성 미생물 또는 식품을 변패를 일으키는 미생물이 리스테리아 모노시토제네스, 리스테리아 모노시토제네스 KCTC 3569, 스타필로코커스 오레우스, 락토바실러스 플란타럼 KCCM 11322, 락토바실러스 플란타럼 L155, 락토바실러스 플란타럼 L165, 락토바실러스 플란타럼 L167, 락토바실러스 애시도필러스 NOCKS, 락토바실러스 애시도필러스 KCCM 32820, 락토바실러스 애시도필러스 CH5, 락토바실러스 애시도필러스 GP1B, 락토바실러스 가세리 KCTC 3163, 락토바실러스 크리스파터스 KCCM 41620, 락토바실러스 브레비스 KCCM 35464, 락토바실러스 카제이 YIT 9029, 락토바실러스 카제이 Y1, 락토바실러스 람노수스 GG 및 류코노스톡 메센테로이데스 KCCM 35471 중 어느 하나 이상인 것을 특징으로 하는 페디오코쿠스 스피시스 JNU534에 의해서도 달성된다.In addition, the object of the present invention is that the harmful microorganisms or microorganisms that cause the food to deteriorate Listeria monocytogenes, Listeria monocytogenes KCTC 3569, Staphylococcus aureus, Lactobacillus plantarum KCCM 11322, Lactobacillus plantarum L155, Lactobacillus plantarum L165, Lactobacillus plantarum L167, Lactobacillus ashdophyllus NOCKS, Lactobacillus ashdophilus KCCM 32820, Lactobacillus ashdophyllus CH5, Lactobacillus ashdophilus GP1B, Lactobacillus Bacillus gasser KCTC 3163, Lactobacillus crispatus KCCM 41620, Lactobacillus brevis KCCM 35464, Lactobacillus cascai YIT 9029, Lactobacillus cascai Y1, Lactobacillus rhamnosus GG and Lyukonostock mesenteroides KCCM 35471 It is achieved by pediococcus spice CIS JNU534 characterized by the above .
또한, 본 발명의 상기 목적은 상기 페디오코쿠스 스피시스 JNU534으로부터 생산된 박테리오신이 3.4kDa의 분자량을 갖는 것을 특징으로 하는 페디오코쿠스 스피시스 JNU534에 의해서도 달성된다.In addition, the above object of the present invention is also achieved by Pediococcus spissis JNU534, characterized in that the bacteriocin produced from the Pediococcus spisus JNU534 has a molecular weight of 3.4kDa.
또한, 본 발명의 상기 목적은 상기 페디오코쿠스 스피시스 JNU534으로부터 생산된 박테리오신의 최초 8개의 아미노산 서열은 NH2-Ile-Leu-Leu-Glu-Glu-Leu-Asn-Val인 것을 특징으로 하는 페디오코쿠스 스피시스 JNU534에 의해서도 달성된다.In addition, the above object of the present invention is a pedi, characterized in that the first eight amino acid sequence of the bacteriocin produced from the Pediococcus spissis JNU534 is NH 2 -Ile-Leu-Leu-Glu-Glu-Leu-Asn-Val It is also achieved by Okoccus Spissis JNU534.
또한, 본 발명의 상기 목적은 상기 페디오코쿠스 스피시스 JNU534 또는 그 배양물을 포함하는 천연방부제, 식품 조성물, 사료용 조성물 및 항균 조성물에 의해서도 달성된다.In addition, the above object of the present invention is also achieved by the natural preservative, food composition, feed composition and antimicrobial composition comprising the Pediococcus spissis JNU534 or its culture.
본 발명의 상기 목적과 기술적 구성 및 그에 따른 작용효과에 관한 자세한 사항은 본 발명의 바람직한 실시 예를 도시하고 있는 도면을 참조한 이하 상세한 설명에 의해보다 명확하게 이해될 것이다.Details of the above object, technical configuration and effects according to the present invention will be more clearly understood by the following detailed description with reference to the drawings showing preferred embodiments of the present invention.
1. 항균물질 생산 유산균의 선발 및 배양 조건1. Selection and Culture Conditions of Lactic Acid Bacteria Producing Antibacterial Substances
본 발명의 페디오코쿠스 스피시스 JNU534(기탁기관 : 한국종균협회부설 한국미생물보존센터, 수탁번호 : KCCM-10869P호, 수탁일자 : 2007년 5월 2일)는 김치로부터 분리한 유산균 균주들을 MRS 배지(broth)(Difco, USA)에 접종하고 37℃에서 2회 계대 배양하여 항균활성 측정에 사용하였다. 지시균으로 사용한 유산균은 MRS 배양액에 그람(Gram)(+) 및 그람(-)의 병원성 균을 TS 배지(tryptic soy broth)(Difco, USA)에 접종하여 같은 조건으로 배양하였다.Pediococcus spissis JNU534 of the present invention (depositary organization: Korea Microbiological Conservation Center affiliated with the Korean spawn association, Accession No .: KCCM-10869P, date of deposit: May 2, 2007) is the MRS medium from the lactic acid bacteria strains isolated from kimchi (broth) (Difco, USA) and incubated twice at 37 ℃ was used for antimicrobial activity measurement. The lactic acid bacteria used as indicator bacteria were inoculated in Gram (+) and Gram (-) pathogenic bacteria in TS medium (tryptic soy broth) (Difco, USA) and cultured under the same conditions.
표 1은 상기 MRS 배지 1L의 조성을 나타내고, 표 2는 상기 TS 배지 1L의 조성을 나타내고 있다.Table 1 shows the composition of 1L of the MRS medium, and Table 2 shows the composition of the 1L of TS medium.
2. 박테리오신 생산 균주의 선발 및 동정2. Selection and Identification of Bacteriocin Producing Strains
박테리오신 생산균주의 선발은 한천 확산법(agar-well diffusion method)을 이용하여 수행하였다. Selection of the bacteriocin producing strain was performed using the agar-well diffusion method.
즉, 각 유산균을 MRS 배지에 접종하여 37℃에서 18시간 동안 배양하고 원심분리(13,000rpm, 10min, 4℃)하여 상등액을 회수하였다.That is, the lactic acid bacteria were inoculated in MRS medium, incubated at 37 ° C. for 18 hours, and centrifuged (13,000 rpm, 10 min, 4 ° C.) to recover the supernatant.
이를 각각 pH4.5 및 pH6.5로 조정한 후, 0.45 ㎛-공극 사이즈 멤브레인 필터(pore size membrane filter)(Advantec MFS, USA)로 여과하여 박테리오신 활성을 확인하기 위한 시료로 사용하였다.This was adjusted to pH4.5 and pH6.5, respectively, and then filtered through a 0.45 μm-pore size membrane filter (Advantec MFS, USA) to be used as a sample for confirming bacteriocin activity.
세균 배양 접시(Petri dish)에 멸균된 메탈 보어(metal borer)를 놓은 후 약 15ml의 MRS 고체 배지를 분주하여 굳히고 그 위에 지시균인 포도상구균(Staphylococcus aureus)를 1% 농도로 접종한 TSSA(tryptic soy soft agar)(0.85%)를 중층하여 굳혔다. After placing a sterile metal borer in a petri dish, an aliquot of about 15 ml of MRS solid medium was dispensed and hardened, and TSSA (tryptic) inoculated with 1% concentration of Staphylococcus aureus. soy soft agar) (0.85%) layered and hardened.
상기 메탈 보어를 제거하여 만들어진 웰(well)에 각 균주의 배양 상등액을 180㎕씩 분주하고 37℃에서 18시간 동안 배양한 후 나타나는 억제환의 크기를 통해 지시균의 생육 억제 여부를 관찰하여 박테리오신 활성을 확인하였다.The culture supernatant of each strain was dispensed in a well prepared by removing the metal bore, and the culture supernatant of each strain was dispensed and cultured for 18 hours at 37 ° C. Confirmed.
상기와 같은 방법으로 최종적으로 선발된 유산균은 그람 염색법(Gram stain)을 통해 형태학적 특징을 확인하고 API 50CH 탄수화물 검사 키트(carbohydrate test kit)(Bio Merieux, France)를 이용한 당발효성을 조사하여 ATB 아이데틴피케이션 프로그램(identification program)(Bio Merieux, France)에 입력한 결과를 바탕으로 동정한 결과 본 발명의 페디오코쿠스 스피시스 JNU534와 96.8%의 상동성을 나타냈었다.The lactic acid bacteria finally selected by the above method were confirmed morphological characteristics by Gram staining and ATB by examining sugar fermentation using API 50CH carbohydrate test kit (Bio Merieux, France). As a result of the identification on the basis of the results entered into the identification program (Bio Merieux, France), 96.8% homology with the Pediococcus spissis JNU534 of the present invention was shown.
상기 분석 결과인 당발효 시험결과를 표 3에 정리하였다.The sugar fermentation test results, the analysis results are summarized in Table 3.
+ : 성장, - : 성장하지 않음 +: Growing,-: not growing
3. 배양시간별 세포의 생장 및 박테리오신 생산3. Cell Growth and Bacteriocin Production by Culture Time
박테리오신을 생산하는 유산균을 106 CFU/ml 농도로 MRS 배지에 접종한 후 37℃에서 48시간 동안 배양하면서 3시간 간격으로 생균수와 pH를 측정하였다.The bacteriocin-producing lactic acid bacteria were inoculated in MRS medium at a concentration of 10 6 CFU / ml, followed by incubation at 37 ° C. for 48 hours, and the number of viable cells and pH were measured at 3 hour intervals.
또한 각 시간대의 배양액을 상기 방법과 동일하게 처리하여 얻은 상등액을 이용하여 임계 희석법(critical dilution method)(Hoover and Harlander, 1993)에 의해 박테리오신 활성의 변화를 측정하였다.In addition, the change of bacteriocin activity was measured by the critical dilution method (Hoover and Harlander, 1993) using the supernatant obtained by treating the culture solution in each time zone in the same manner as the above method.
즉, MRS 배지 위에 멸균 증류수로 연속 2진 희석(two-fold dilution)한 상등액을 점적하고 지시균인 락토바실루스 플란티룸(Lactobacillus plantarum)이 접종된 MRS 소프트 배지를 중층하여 37℃에서 18시간 동안 배양한 후 억제환을 확인하였다.That is, a supernatant of two-fold dilution with sterile distilled water was dropped on the MRS medium, and the MRS soft medium inoculated with Lactobacillus plantarum, which is an indicator bacterium, was incubated at 37 ° C. for 18 hours. After the suppression was confirmed.
하기의 표 4는 상기 선발 박테리오신의 항균 활성을 나타내는 것으로 상기에서 동정된 균주를 이용하여 11종의 병원성 균과 19종의 유산균에 대한 생육 저해활성을 평가한 결과를 나타낸 것이다.Table 4 below shows the antimicrobial activity of the selected bacteriocin and shows the results of evaluating the growth inhibitory activity against 11 pathogenic bacteria and 19 lactic acid bacteria using the strains identified above.
+ : 억제됨, - : 억제되지 않음.+: Suppressed,-: not suppressed.
상기 표 4에서 보는 바와 같이 리스테리아 모노시토제네스(Listeria monoctogenes), 리스테리아 모노시토제네스(Listeria monoctogenes) KCTC 3569, 스타필로코커스 오레우스(staphylococcus aureus), 락토바실러스 플란타럼(Lactobacillus plantarum) KCCM 11322, 락토바실러스 플란타럼(Lactobacillus plantarum) L155, 락토바실러스 플란타럼(Lactobacillus plantarum) L165 락토바실러스 플란타럼(Lactobacillus plantarum) L167, 락토바실러스 애시도필러스(Lactobacillus acidophilus) NOCKS, 락토바실러스 애시도필러스(Lactobacillus acidophilus) KCCM 32820, 락토바실러스 애시도필러스(Lactobacillus acidophilus) CH5, 락토바실러스 애시도필러스(Lactobacillus acidophilus) GP1B, 락토바실러스 가세리(Lactobacillus gasseri) KCTC 3163, 락토바실러스 크리스파터스(Lactobacillus crispatus) KCCM 41620, 락토바실러스 브레비스(Lactobacillus brevis) KCCM 35464, 락토바실러스 카제이(Lactobacillus casei) YIT 9029, 락토바실러스 카제이(Lactobacillus casei) Y1, 락토바실러스 람노수스(Lactobacillus rhamnosus) GG 및 류코노스톡 메센테로이데스(Leuconostoc mesenteroides) KCCM 35471 등에 대해서는 항균활성을 나타내고 있으나 대장균(E. coli), 장티프스균(Salmonella typhimurium), 크렙시엘라 뉴모니에(Klebsiella pneumoniae), 엔테로박터 에어로제너스(Enterobacter aerogenes) 등 그람(-)균의 생육은 저해하지 못했다.As shown in Table 4, Listeria monoctogenes, Listeria monoctogenes KCTC 3569, Staphylococcus aureus, Lactobacillus plantarum KCCM 11322, Lactobacillus Lactobacillus plantarum L155, Lactobacillus plantarum L165 Lactobacillus plantarum L167, Lactobacillus acidophilus NOCKS, Lactobacillus ashdophyllus Lactobacillus acidophilus KCCM 32820, Lactobacillus acidophilus CH5, Lactobacillus acidophilus GP1B, Lactobacillus gasseri KCTC 3163, Lactobacillus crispapatus crispatus KCCM 41620, Lactobacillus brevis KCCM 35464, Lactobacillus Lactobacillus casei YIT 9029, Lactobacillus casei Y1, Lactobacillus rhamnosus GG, and Leuconostoc mesenteroides KCCM 35471 show antibacterial activity (E. coli), Salmonella typhimurium, Klebsiella pneumoniae, Enterobacter aerogenes, etc. did not inhibit the growth of gram (-) bacteria.
4. 박테리오신의 정제4. Purification of Bacteriocin
본 발명의 페디오코쿠스 스피시스 JNU534를 2회 계대 배양한 후, MRS 배지 1,000ml에 1%농도로 접종하여 18시간 배양한 후 원심분리(8,000rpm, 30min, 4℃)하여 상등액을 회수하였다.After two passages of Pediococcus spissis JNU534 of the present invention, the supernatant was recovered by centrifugation (8,000rpm, 30min, 4 ° C) after incubating for 18 hours by inoculating 1% concentration in 1,000 ml of MRS medium.
상기 배양 상등액에 황산암모늄(ammonium sulfate)을 30% 농도로 첨가하면서 12시간 이상 4℃에서 서서히 교반시킨 후 다시 원심분리(8,000rpm, 30min, 4℃)하였다.Ammonium sulfate was added to the culture supernatant at a concentration of 30% and stirred slowly at 4 ° C. for at least 12 hours, followed by centrifugation (8,000 rpm, 30 min, 4 ° C.).
여기서 얻어진 침전물을 50mM MES(2-(4-morpholino)-ethane sulfonic acid)(Sigma, USA) 버퍼(pH 7.0) 50ml에 용해시켜 제조한 조박테리오신(crude bacteriocin) 용액을 -20℃에 보관하며 사용하였다. A crude bacteriocin solution prepared by dissolving the precipitate obtained in 50 ml of 50 mM MES (2- (4-morpholino) -ethane sulfonic acid) (Sigma, USA) buffer (pH 7.0) was stored at -20 ° C. It was.
1.7M 황산암모늄의 3 베드 용적(bed volume)으로 평형화된 옥틸-세파로스 CL-4B 컬럼(Octyl-Sepharose CL-4B column)(Bio-rad, USA)에 조박테리오신 용액을 주입하여 크로마토그래피(chromatography)를 실시하였다.Chromatography was performed by injecting a Zobacteriocin solution into an Octyl-Sepharose CL-4B column (Bio-rad, USA) equilibrated to a three bed volume of 1.7 M ammonium sulfate. ) Was performed.
상기 조박테리오신 용액을 이용하여 수소성결합 컬럼 크로마토그래피(hydrophobic interaction coumn chromatography)를 실시한 결과를 도 1에 도시하고 있는데, 총 78개의 분획 중에서 6개의 박테리오신 활성 분획을 분리하였으며 이중에서 214nm에서의 흡광도 측정 결과 나타난 피크(peak)와 일치하며 가장 높은 박테리오신 활성(400 AU/ml)을 보이는 분획을 전기영동 시료로 사용하였다. Hydrophobic interaction column chromatography using the crude bacteriocin solution is shown in FIG. 1. Six bacteriocin active fractions were isolated from a total of 78 fractions, and the absorbance at 214 nm was measured. Fractions consistent with the resulting peak and showing the highest bacteriocin activity (400 AU / ml) were used as electrophoretic samples.
이를 통해 얻은 분획에 대하여 214nm에서의 흡광도를 측정하고 지시균에 대한 항균물질 생산 여부를 확인한 후 항균활성을 나타낸 분획만을 회수하여 각각의 박테리오신 활성을 측정하였다.The absorbance at 214nm was measured for the fractions obtained, and after confirming the production of antimicrobial substances against indicator bacteria, only the fractions showing the antimicrobial activity were recovered and the respective bacteriocin activities were measured.
가장 높은 박테리오신 활성을 보인 분획을 -70℃에서 동결시킨 뒤 건조, 농축하고 2×트리신-SDS 샘플 버퍼(tricine-SDS sample buffer)(Novex, USA)에 용해시켜 전기영동 시료로 사용하였다.Fractions showing the highest bacteriocin activity were frozen at −70 ° C., dried, concentrated, dissolved in 2 × tricine-SDS sample buffer (Novex, USA) and used as electrophoretic samples.
상기 전기영동은 4%의 스택킹 겔(stacking gel), 10%의 스페이서 겔(spacer gel) 및 16%의 세퍼레이팅 겔(separaging gel)을 제조하여 미니-프로티안 3셀(Mini-PROTEAN 3cell)(Bio-Rad, USA)을 사용하여 125V의 일정한 전압으로 60분 동안 트리신-SDS-페이지(Tricine-SDS-PAGE)(Schagger and Von Jagow, 1987)를 실시하였다.The electrophoresis was performed by preparing a 4% stacking gel, a 10% spacer gel, and a 16% separation gel to produce a mini-PROTEAN 3cell. Tri-SDS-PAGE (Schagger and Von Jagow, 1987) was performed for 60 minutes at a constant voltage of 125 V using (Bio-Rad, USA).
상기 전기영동이 완료된 겔은 미니 트랜스-볼트 셀(Mini Trans-Blot Cell)(Bio-Rad, USA)을 이용하여 4℃에서 50V의 일정한 전압으로 3시간 동안 PVDF(polyvinylidene difluoride) 멤브레인에 블로팅(blotting)하였다. The electrophoresis-completed gel was blotted onto a polyvinylidene difluoride (PVDF) membrane for 3 hours at a constant voltage of 50 V at 4 ° C. using a Mini Trans-Blot Cell (Bio-Rad, USA). blotting).
상기 압지가 완료된 멤브레인을 에드만 분해(Edman degradation)에 의한 N-터미널 서열 결정(N-terminal sequencing)을 실시하였다.N-terminal sequencing was performed by Edman degradation of the bloated membrane.
상기 에드만 분해에 의해 아미노산 서열을 분석한 결과 최초의 8개 아미노산만 NH2-Ile-Leu-Leu-Glu-Glu-Leu-Asn-Val로 판독되었으며 9번째 서열부터는 블록킹(blocking)되어 분석하지 못하였다.As a result of analyzing the amino acid sequence by Edman digestion, only the first 8 amino acids were read as NH 2 -Ile-Leu-Leu-Glu-Glu-Leu-Asn-Val, and from the ninth sequence, blocking was not performed. I couldn't.
5. 박테리오신의 특성5. Characteristics of Bacteriocin
회수한 상등액을 5N NaOH를 이용하여 pH 6.5로 조정하고 0.45㎛-공극 사이즈 멤브레인 필터로 여과한 후 다음과 같이 실시하였다.The collected supernatant was adjusted to pH 6.5 using 5N NaOH, filtered through a 0.45 μm-pore size membrane filter, and then carried out as follows.
항온 수조 및 오토클레이브(Autoclave)를 이용하여 상등액을 다양한 온도(37, 70, 80, 90, 100, 121℃)로 15분 동안 가열하고 상온으로 냉각시켜 항균활성을 측정한 후 열처리를 하지 않은 대조구와 비교하여 박테리오신 활성의 변화를 조사한 결과, 도 2에서 보는 바와 같이 37, 70, 80, 90 및 100℃로 15분간 열처리한 경우에는 박테리오신의 활성이 소실되지 않고 유지되었으나 121℃에서는 완전히 소실되었다.Controlled supernatant using a constant temperature bath and autoclave for 15 minutes at various temperatures (37, 70, 80, 90, 100, 121 ℃) and cooled to room temperature to measure the antimicrobial activity and then not heat treated As a result of investigating changes in bacteriocin activity, as shown in FIG. 2, when heat treated at 37, 70, 80, 90 and 100 ° C. for 15 minutes, the activity of bacteriocin was maintained without being lost, but completely disappeared at 121 ° C.
따라서, 본 발명의 페디오코쿠스 스피시스 JNU534는 약 100℃ 이하의 온도에서는 소실되지 않는 것을 보여주고 있다.Thus, the Pediococcus spissis JNU534 of the present invention shows that it does not disappear at temperatures below about 100 ° C.
항균효과를 보이는 물질이 단백질성 물질인지 여부를 알아보기 위하여 트립신(Trypsin)(Sigma, USA), 리소자임(lysozyme)(Sigma, USA), 프로테아제(protease)(Sigma, USA)는 50mM Tris-HCl 완충액(pH 7.5), 펩신(pepsin)(Sigma, USA)은 50mM 구연산염(citrate) 완충액(pH 2.0), 프로테이나제 K(proteinase K)(USB, USA)는 10mM Tris-HCl-50mM NaCl-5mM EDTA(pH 7.5)에 각각 용해시켜 효소액을 제조하였다.Trypsin (Sigma, USA), lysozyme (Sigma, USA), and protease (Sigma, USA) are 50 mM Tris-HCl buffers to determine whether the antimicrobial agents are proteinaceous. pH 7.5, pepsin (Sigma, USA) 50 mM citrate buffer (pH 2.0), proteinase K (USB, USA) 10 mM Tris-HCl-50 mM NaCl-5 mM Each was dissolved in EDTA (pH 7.5) to prepare an enzyme solution.
이를 박테리오신 용액에 각각 4mg/ml 농도로 첨가하여 37℃ 항온 수조에서 12시간 동안 반응시킨 후 박테리오신 활성을 측정하였다. 대조구로는 동일한 조건에서 효소액을 처리하지 않은 것을 사용하였다.This was added to the bacteriocin solution at a concentration of 4 mg / ml, respectively, and reacted in a 37 ° C. constant temperature water bath for 12 hours, and then the bacteriocin activity was measured. As a control, one that was not treated with enzyme solution under the same conditions was used.
상기 박테리오신 활성 결과는 도 3에서 보는 바와 같이, 세포벽의 다당류 사슬을 분해하는 효소인 리소자임에 의해서는 박테리오신 활성이 유지되었으나 단백질 가수분해효소인 트립신, 펩신, 프로테아제 및 프로테이나제 K에 의해서는 박테리오신 활성이 제거됨으로써 단백질성 물질임을 확인할 수 있었으므로 보존제로서의 안전성이 매우 높을 것으로 여겨진다.As shown in Figure 3, the bacteriocin activity was maintained by lysozyme, an enzyme that breaks down the polysaccharide chain of the cell wall, but bacteriocin was maintained by proteinases trypsin, pepsin, protease and proteinase K. Since the activity was removed, it was confirmed that it is a proteinaceous material, and thus, the safety as a preservative is considered to be very high.
따라서, 본 발명의 페디오코쿠스 스피시스 JNU534는 리스테리아 모노시토제네스, 리스테리아 모노시토제네스 KCTC 3569, 스타필로코커스 오레우스, 락토바실러스 플란타럼 KCCM 11322, 락토바실러스 플란타럼 L155, 락토바실러스 플란타럼 L165, 락토바실러스 플란타럼 L167, 락토바실러스 애시도필러스 NOCKS, 락토바실러스 애시도필러스 KCCM 32820, 락토바실러스 애시도필러스 CH5, 락토바실러스 애시도필러스 GP1B, 락토바실러스 가세리 KCTC 3163, 락토바실러스 크리스파터스 KCCM 41620, 락토바실러스 브레비스 KCCM 35464, 락토바실러스 카제이 YIT 9029, 락토바실러스 카제이 Y1, 락토바실러스 람노수스 GG 및 류코노스톡 메센테로이데스 KCCM 35471 등과 같은 유해한 미생물과 식품의 변패를 일으키는 미생물의 생육을 억제시키는 항균능력을 가지고 있어 페디오코쿠스 스피시스 JNU534 자체 또는 그 배양물을 천연방부제, 식품 조성물, 사료용 조성물 및 항균 조성물로 이용할 수 있다.Thus, the Pediococcus spissis JNU534 of the present invention is Listeria monocytogenes, Listeria monocytogenes KCTC 3569, Staphylococcus oreus, Lactobacillus plantarum KCCM 11322, Lactobacillus plantarum L155, Lactobacillus plantarum L165, Lactobacillus plantarum L167, Lactobacillus ashdophyllus NOCKS, Lactobacillus ashdophyllus KCCM 32820, Lactobacillus ashdophyllus CH5, Lactobacillus ashdophilus GP1B, Lactobacillus gasseri KCTC 3163, Lactobacillus Harmful microorganisms and foods such as Bacillus crispatus KCCM 41620, Lactobacillus brevis KCCM 35464, Lactobacillus cascai YIT 9029, Lactobacillus cascai Y1, Lactobacillus rhamnosus GG, and leukonostock mesenteroides KCCM 35471 Pediococcus spissis with antibacterial ability to restrain microbial growth JNU534 itself or its culture can be used as a natural preservative, food composition, feed composition and antimicrobial composition.
따라서, 본 발명의 페디오코쿠스 스피시스 JNU534는 병원성 미생물과 부패성 미생물 등의 유해한 미생물의 생육을 억제시키는 항균능력을 가지고 있어 천연방부 제, 식품 조성물, 사료용 조성물 및 항균 조성물으로 이용될 수 있어 산업상에 매우 폭넓게 활용될 수 있는 효과가 있다.Therefore, the Pediococcus spis JNU534 of the present invention has an antimicrobial ability to inhibit the growth of harmful microorganisms, such as pathogenic microorganisms and decaying microorganisms can be used as natural preservatives, food compositions, feed compositions and antimicrobial There is an effect that can be used very widely.
본 발명은 이상에서 살펴본 바와 같이 바람직한 실시 예를 들어 도시하고 설명하였으나, 상기한 실시 예에 한정되지 아니하며 본 발명의 정신을 벗어나지 않는 범위 내에서 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자에 의해 다양한 변경과 수정이 가능할 것이다.Although the present invention has been shown and described with reference to preferred embodiments as described above, it is not limited to the above-described embodiments and those skilled in the art without departing from the spirit of the present invention. Various changes and modifications will be possible.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070060639A KR100890462B1 (en) | 2007-06-20 | 2007-06-20 | Pediococcus spissis JNU44 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070060639A KR100890462B1 (en) | 2007-06-20 | 2007-06-20 | Pediococcus spissis JNU44 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080111990A KR20080111990A (en) | 2008-12-24 |
KR100890462B1 true KR100890462B1 (en) | 2009-03-26 |
Family
ID=40370030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070060639A Active KR100890462B1 (en) | 2007-06-20 | 2007-06-20 | Pediococcus spissis JNU44 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100890462B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101835809B1 (en) * | 2016-02-29 | 2018-03-12 | 전남대학교산학협력단 | Preparing method for yogurt |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101215422B1 (en) * | 2010-04-06 | 2013-01-09 | 우리생명과학(주) | Pediococcus acidilactici WRL-1 and use of the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4929445A (en) * | 1988-01-25 | 1990-05-29 | Microlife Technics, Inc. | Method for inhibiting Listeria monocytogenes using a bacteriocin |
KR20020012171A (en) * | 1999-04-09 | 2002-02-15 | 부쳐-랄슨 에이. | Novel protective cultures and use thereof for preserving foodstuffs |
KR20040010415A (en) * | 2002-08-14 | 2004-01-31 | 주식회사 이롬라이프 | Novel Pediococcus pentosaceus EROM101 having immune enhancement, anticancer and antibacterial activities |
KR20040080078A (en) * | 2003-03-10 | 2004-09-18 | 한국식품개발연구원 | E.coli O157:H7 Inhibiting Agent Comprising P. acidilactici or/and Bacteriocin and Effective Amount of Lactic Acid, and Preservation Method of Food |
-
2007
- 2007-06-20 KR KR1020070060639A patent/KR100890462B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4929445A (en) * | 1988-01-25 | 1990-05-29 | Microlife Technics, Inc. | Method for inhibiting Listeria monocytogenes using a bacteriocin |
KR20020012171A (en) * | 1999-04-09 | 2002-02-15 | 부쳐-랄슨 에이. | Novel protective cultures and use thereof for preserving foodstuffs |
KR20040010415A (en) * | 2002-08-14 | 2004-01-31 | 주식회사 이롬라이프 | Novel Pediococcus pentosaceus EROM101 having immune enhancement, anticancer and antibacterial activities |
KR20040080078A (en) * | 2003-03-10 | 2004-09-18 | 한국식품개발연구원 | E.coli O157:H7 Inhibiting Agent Comprising P. acidilactici or/and Bacteriocin and Effective Amount of Lactic Acid, and Preservation Method of Food |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101835809B1 (en) * | 2016-02-29 | 2018-03-12 | 전남대학교산학협력단 | Preparing method for yogurt |
Also Published As
Publication number | Publication date |
---|---|
KR20080111990A (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Todorov et al. | Bacteriocinogenic Lactobacillus plantarum ST16Pa isolated from papaya (Carica papaya)—From isolation to application: Characterization of a bacteriocin | |
Janes et al. | Identification and characterization of two bacteriocin-producing bacteria isolated from garlic and ginger root | |
Yildirim et al. | Characterization and antimicrobial spectrum of bifidocin B, a bacteriocin produced by Bifidobacterium bifidum NCFB 1454 | |
JP6709208B2 (en) | New Lactobacillus strain and its use | |
Gonzalez et al. | Detection, purification, and partial characterization of plantaricin C, a bacteriocin produced by a Lactobacillus plantarum strain of dairy origin | |
Abo-Amer | Characterization of a bacteriocin-like inhibitory substance produced by Lactobacillus plantarum isolated from Egyptian home-made yogurt | |
Ahmed et al. | Lactobacillus acidophilus bacteriocin, from production to their application: An overview | |
Pal et al. | Isolation and characterization of bacteriocin producing lactic acid bacteria from a South Indian Special dosa (Appam) batter | |
Bennik et al. | Vegetable-associated Pediococcus parvulus produces pediocin PA-1 | |
EP2592158A1 (en) | Lactobacillus plantarum species possessing broad spectrum anti-fungal activity and exhibiting high heat tolerance and osmotolerance | |
Şahingil et al. | Characterization of lactococcin BZ produced by Lactococcus lactis subsp. lactis BZ isolated from boza | |
US5908646A (en) | Inhibition of clostridia with lactic acid bacteria | |
Olasupo et al. | Bacteriocin production by Enterococcus faecium NA01 from ‘wara’—a fermented skimmed cow milk product from West Africa | |
Kato et al. | Complete growth inhibition of Bacillus subtilis by nisin-producing lactococci in fermented soybeans | |
KR100890462B1 (en) | Pediococcus spissis JNU44 | |
KR20050106022A (en) | Control of enzymatic degradation of glucosinolates by lactic acid bacterium | |
Hemme | Leuconostoc and its use in dairy technology | |
KR101302465B1 (en) | Lactic acid bacterium separated from kimchii and fermented food using the strain | |
US20040208978A1 (en) | Novel lactic acid bacteria and bacteriocins produced therefrom, and method for processing fish and legume foodstuffs using the same and the products obtained thereby | |
Aslam et al. | Production optimization and characterization of a low molecular weight bacteriocin from Lactococcus lactis subsp. lactis | |
Mojgani et al. | Characterization of bacteriocins produced by Lactobacillus brevis NM 24 and L. fermentum NM 332 isolated from green olives in Iran | |
KR100528641B1 (en) | Leuconostoc citreum gj7 and bacteriocin produced from same | |
Zamfir et al. | Impact of stress conditions on the growth of Lactobacillus acidophilus IBB 801 and production of acidophilin 801 | |
Kawahara et al. | Characterization of multiple bacteriocin-producing Lactiplantibacillus plantarum PUK6 isolated from misozuke-tofu | |
KR100509558B1 (en) | Lactobacillus plantarum j9 and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20070620 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080922 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20081216 |
|
PG1501 | Laying open of application | ||
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20090318 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20090319 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20120319 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20130201 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20130201 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140203 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20140203 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150130 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20150130 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160316 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20160316 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170118 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20170118 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180209 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20180209 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20200219 Year of fee payment: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20200219 Start annual number: 12 End annual number: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20210302 Start annual number: 13 End annual number: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20230201 Start annual number: 15 End annual number: 15 |
|
PR1001 | Payment of annual fee |
Payment date: 20240205 Start annual number: 16 End annual number: 16 |
|
PR1001 | Payment of annual fee |
Payment date: 20250318 Start annual number: 17 End annual number: 17 |